What new risks are associated with GLP-1 medications?

New research suggests GLP-1 medications may increase the risk of skeletal disorders like osteoporosis and gout, as well as tendon ruptures.

What is the increased risk of osteoporosis with GLP-1 drugs?

Over five years, patients taking GLP-1 medications faced a nearly 30 percent higher risk of developing osteoporosis.

Are there concerns about tendon health with GLP-1 use?

Yes, GLP-1 use has been associated with a roughly 50 percent increased risk of several types of tendon ruptures over five years.

Home / Health / GLP-1 Drugs Linked to Bone and Tendon Woes

GLP-1 Drugs Linked to Bone and Tendon Woes

8 Mar

•

Summary

GLP-1 users face higher risks of osteoporosis and gout.
Tendon rupture risk increases significantly with GLP-1 use.
New research suggests potential bone and tendon structural impacts.

GLP-1 Drugs Linked to Bone and Tendon Woes

New research presented this week suggests that GLP-1 medications, commonly prescribed for weight loss, may lead to significant skeletal issues. An analysis involving nearly 150,000 patients indicated a higher risk of bone disorders, including a nearly 30 percent increase in osteoporosis over five years.

The study also highlighted a 12 percent rise in gout risk and over a 150 percent increase in osteomalacia. Furthermore, GLP-1 use was associated with a roughly 50 percent increased risk of various tendon ruptures over the same period.

These findings raise pressing questions about the long-term effects on bone density and tendon integrity. While pharmaceutical companies are reportedly developing newer versions to mitigate these risks, current prescriptions for drugs like Ozempic and Wegovy do not fully detail these potential adverse reactions.